Three ( 1 % ) of 329 patients in the tofacitinib 5 mg group , ten ( 3 % ) of 330 in the tofacitinib 10 mg group , 11 ( 3 % ) of 335 in the etanercept group , and four ( 4 % ) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events .